The introduction of troglitazone, a potent antidiabetic agent, marked a significant chapter in the management of type 2 diabetes. However, its removal from the market due to serious hepatotoxicity spurred extensive investigation into related thiazolidinediones. Following pioglitazone and rosiglitazone emerged, offering akin mechanisms of action –